Affordable Drug Manufacturing Act of 2023

The Affordable Drug Manufacturing Act of 2023 establishes a new Office of Drug Manufacturing within the Department of Health and Human Services to directly manufacture and sell specific prescription drugs. It prioritizes drugs with expired patents or limited manufacturers (like insulin, asthma inhalers, naloxone, epinephrine injectors, and antibiotics) that face high costs or shortages, requiring the Office to produce at least 15 such drugs within one year and 25 within three years. The Office sets "fair prices" based on manufacturing costs, patient access, and impact on competition, while mandating public transparency in all pricing and requiring federal agencies to purchase these drugs. This directly affects patients and consumers by aiming to lower costs and improve access to essential medications through government-manufactured alternatives.